Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 4/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | ACACA | Q13085 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2113744 | 0.82 | LCK (0.51) | LCKMAPK1 | |
| SCHEMBL30711674 | 0.82 | LCK (0.51) | LCKMAPK1 | |
| SCHEMBL4721570 | 0.80 | MAPK1 (0.45) | LCKCNR2MAPK1 | |
| SCHEMBL23467642 | 0.79 | LCK (0.48) | LCKSCN9AGSK3BDYRK1ACA12 | |
| SCHEMBL21590399 | 0.79 | CYP1A2 (0.41) | LCKSCN9AGSK3BDYRK1ACYP2C9 | |
| SCHEMBL20355066 | 0.79 | SCN9A (0.46) | LCKSCN9ACYP17A1GSK3BDYRK1A | |
| SCHEMBL30483586 | 0.78 | KDM4A (0.42) | LCKDYRK1AACACBACACACA12 | |
| SCHEMBL1940483 | 0.77 | IGF1R (0.48) | LCKSCN9ACYP17A1GSK3BDYRK1A | |
| SCHEMBL22208004 | 0.77 | AAK1 (0.40) | LCKSCN9ACYP17A1GSK3BDYRK1A | |
| SCHEMBL20302320 | 0.77 | LCK (0.46) | LCKSCN9AGSK3BDYRK1AACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136790-A1 | Tricyclic Heterocyclic Derivatives and Methods of Use | DE LERA RUIZ MANUEL | 2011-06-09 | — | — | US | disclosed |
| EP-2318391-A1 | TRICYCLIC HETEROCYCLE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | Schering Corporation (US) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010011653-A1 | TRICYCLIC HETEROCYCLE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | SCHERING CORPORATION (US) | 2010-01-28 | — | — | WO | disclosed |
| US-7638531-B2 | Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7531660-B2 | 1-[[1-[(2-amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-B]pyridin-3-YL]piperidine and methods of use thereof | SCHERING CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531660-B2 | 1-[[1-[(2-amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-B]pyridin-3-YL]piperidine and methods of use thereof | SCHERING CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080058370-A1 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine and Methods of Use Thereof | SCHERING CORPORATION | 2008-03-06 | — | — | US | disclosed |
| US-20080058370-A1 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine and Methods of Use Thereof | SCHERING CORPORATION | 2008-03-06 | — | — | US | disclosed |
| US-7332604-B2 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine | SCHERING CORPORATION (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332604-B2 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine | SCHERING CORPORATION (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070167435-A1 | Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| WO-2007075629-A2 | PHENOXYPIPERIDINES AND ANALOGS THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS | SCHERING CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007035703-A1 | 1- [ [1- [ (2-AMIN0-6-METHYL-4-PYRIDINYL) METHYL] -4-FLU0R0-4-PIPERIDINYL,] CARBONYL] -4- [2- (2-PYRIDINYL) -3H-IMIDAZ0 [4 , 5-B] PYRIDIN-3-YL] PIPERIDINE USEFUL AS HISTAMINE H3 ANTAGONIST | SCHERING CORPORATION (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20070066644-A1 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine | SCHERING CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066644-A1 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine | SCHERING CORPORATION | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167435-A1 | Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists | HRH4, HRH3, HRH2 | LCK 2674/4885SCN9A 2949/4885CNR2 13/4885 |
| US-20070066644-A1 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine | FABP1, GPR119, FABP4 | LCK 2845/4885SCN9A 3571/4885CNR2 443/4885 |
| US-20110136790-A1 | Tricyclic Heterocyclic Derivatives and Methods of Use | GPR119, CNR1, CNR2 | LCK 2924/4885SCN9A 1631/4885CNR2 3/4885 |
| US-20080058370-A1 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine and Methods of Use Thereof | FABP1, LIPC, GPR119 | LCK 2811/4885SCN9A 3916/4885CNR2 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.